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Abstract
Background
Triiodothyronine (T3) and thyroxine (T4) as the main secretion products of the thyroid affect
nearly every human tissue and are involved in a broad range of processes ranging from
energy expenditure and lipid metabolism to glucose homeostasis. Metabolomics studies
outside the focus of clinical manifest thyroid diseases are rare. The aim of the present inves-
tigation was to analyze the cross-sectional and longitudinal associations of urinary metabo-
lites with serum free T4 (FT4) and thyroid-stimulating hormone (TSH).
Methods
Urine Metabolites of participants of the population-based studies Inter99 (n = 5620) and
Health2006/Health2008 (n = 3788) were analyzed by 1H-NMR spectroscopy. Linear or
mixed linear models were used to detect associations between urine metabolites and thy-
roid function.
Results
Cross-sectional analyses revealed positive relations of alanine, trigonelline and lactic acid
with FT4 and negative relations of dimethylamine, glucose, glycine and lactic acid with log
(TSH). In longitudinal analyses, lower levels of alanine, dimethylamine, glycine, lactic acid
and N,N-dimethylglycine were linked to a higher decline in FT4 levels over time, whereas
higher trigonelline levels were related to a higher FT4 decline. Moreover, the risk of hypothy-
roidism was higher in subjects with high baseline trigonelline or low lactic acid, alanine or
glycine values.
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Conclusion
The detected associations mainly emphasize the important role of thyroid hormones in glu-
cose homeostasis. In addition, the predictive character of these metabolites might argue for
a potential feedback of the metabolic state on thyroid function. Besides known metabolic
consequences of TH, the link to the urine excretion of trigonelline, a marker of coffee con-
sumption, represents a novel finding of this study and given the ubiquitous consumption of
coffee requires further research.
Introduction
A normal thyroid function is crucial to maintain physiological actions including growth,
development as well as regulation of metabolism and thermogenesis [1, 2]. The thyroid hor-
mones (TH), triiodothyronine (T3) and thyroxine (T4), are central components of the hypo-
thalamic-pituitary-thyroid axis and are involved in a broad range of processes ranging from
energy expenditure and lipid metabolism to glucose homeostasis [1]. The physiological impor-
tance of both THs is widely accepted as THs nearly affect every human tissue [2]. The unbound
fraction of T4 (FT4)—only 0.03% of T4 is free in the circulation [2]—plays a key role in clinical
decision making with regard to the thyroid function together with thyroid-stimulating hor-
mone (TSH) [3, 4].
Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy based meta-
bolomics are used to detect physiological or pathological changes in cells, tissues or body fluids
and activity of metabolic pathways. In recent years, these techniques have been used to gain
deeper insights in both thyroid cancer progression [5] and THs-mediated regulation of metab-
olism [6–11]. Experimental rodent studies have investigated the metabolic profile of hypothy-
roidism. The studies revealed that several urine and serum metabolites involved in energy
metabolism, amino acid (AA) metabolism, sphingolipid metabolism and purine metabolism
were altered after the induction of hypothyroidism [6, 7]. Furthermore, a decline in the meta-
bolic activity in cerebellum in a hypothyroid state was reported [8]. Large scaled human stud-
ies are however rare [9–11]. An analysis based on targeted serum metabolomics of nearly 1500
euthyroid subjects found associations between FT4 levels, but not TSH, and acylcarnitines or
phosphatidylcholines and concluded that FT4 is linked to an increased β-oxidation [9].
Another study using urine samples of over 3300 subjects further highlighted the distinct
actions of FT4 and TSH on amino acid, methane or phospholipid metabolism [10]. Whereas
FT4 showed associations with gluconeogenic AAs and metabolites of the methane metabolism
which argues for a relevant role in energy metabolism, TSH was linked to urinary levels of
tyrosine and hippurate suggesting a role in the phenylalanine and tyrosine metabolism. Fur-
thermore, based on the same analytical approach, associations of urinary metabolites including
trigonelline, pyroglutamate, acetone and hippurate with the TH metabolite 3,5-diiodo-L-thyr-
onine (3,5-T2) were found as well [11].
The aim of the present investigation was to analyze the associations between 17 urinary
metabolites and serum FT4 and TSH by using non-targeted 1H-NMR measurements in two
population-based studies comprising over 9400 subjects.
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Material and methods
Study populations
All population-based studies were performed at the Research Centre for Prevention and
Health, The Capital Region of Denmark. Written informed consent was obtained from all par-
ticipants and the Inter99 (KA 98155), Health2006 (KA-20060011) and Health2008
(H-KA20060011) were approved by the regional Ethical Committee and the Danish Data Pro-
tection Agency. Furthermore, the present project was approved by the Ethics Committee of
the Capital Region of Denmark (H-15004167) and the Danish Data Protection Agency.
The Inter99 study. The Inter99 is a randomized population-based intervention study initi-
ated in March 1999 and ended in April 2006. The study design and the intervention have been
described in detail elsewhere [12] and can be found on the website http://www.inter99.dk. The
individuals were drawn from the Civil Registration System. The study population (N = 61,301)
comprised all individuals in specific age-groups (30, 35, 40, 45, 50, 55 and 60 years) from a
defined area of Copenhagen. From this study population 13,016 persons were drawn for the
intervention and 6784 participants (52.5%) accepted and were examined at baseline.
NMR measurements were available for 6184 of the baseline participants. For cross-sectional
analyses, 289 subjects without FT4 and TSH measurements and additionally 258 subjects with-
out information about confounding factors were excluded resulting in a final Inter99 study
population of 5620 subjects. For longitudinal analyses two different statistical analyses were
applied (Fig 1) leading to two different study populations after exclusion of missing data for
FT4, TSH, metabolites or confounders: 1) association between metabolite levels and changes
in FT4 and TSH (mixed linear regression: n = 5117 observations of 2396 subjects, using of
baseline, 1-yr, 3-yr and 5-yr information) and 2) association between baseline metabolite levels
and risk of hypo- and hyperthyroidism (multinomial logistic regression: n = 3393 subjects,
using only subjects with complete baseline and 5-yr follow-up information and without base-
line thyroid diseases).
The Health2006/08 study. Health2006 participants (N = 3471, participation rate: 44.7%)
or Health2008 participants (N = 795) were recruited from June 2006 to May 2008 or Septem-
ber 2008 to December 2009 from the Danish Central Personal Register, as a random sample
from persons living in the western area of the Capital Region of Denmark, respectively. Based
on both studies, for 4000 participants NMR measurements were available. Of these subjects,
173 subjects without FT4 and TSH measurements and additionally 39 subjects without infor-
mation about confounding factors were excluded. The final Health2006/08 study population
comprised 3788 subjects for cross-sectional analyses.
Measurements
The Inter99 study. Information on coffee consumption was assessed by questionnaire.
Height and weight were measured without shoes and with light clothes. Body mass index
(BMI) was calculated as weight (kg) divided by height (m) squared. All participants had their
blood pressure measured twice with a mercury sphygmomanometer (Mercuro 300; Speidel &
Keller GmbH & Co, Jungingen, Germany) with appropriate cuff size, after 5 min of rest, in the
lying position, and the average of the recorded measurements was used. Hemoglobin A1c
(HbA1c) was measured for all participants by principles of ion exchange HPLC using Bio-Rad
VARIANT ™ Hemoglobin A1C (BioRad, USA). Low-density lipoprotein (LDL) cholesterol was
measured using enzymatic colorimetric methods (Roche, Mannheim, Germany).
The Health2006/08 study. Height and weight were measured without shoes and with
light clothes. Body mass index (BMI) was calculated as weight (kg) divided by height (m)
Urinary metabolic profile of thyroid function
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squared. Blood pressure was measured in the sitting position after 5 minutes of rest using a
Mercury300 mercury phygmomanometer, and the mean of two values was used for systolic
and for diastolic pressure. Systolic blood pressure was read at the first Korotkoff sound and
diastolic blood pressure at the disappearance of the Korotkoff sounds (phase V). The deflation
rate was 2 mmHg/second. Before the investigation, the manometer was calibrated. Fasting
blood samples were analyzed for HbA1c (BioRad, USA). LDL cholesterol was measured using
enzymatic colorimetric methods (Roche, Mannheim, Germany).
Thyroid hormones
For Inter99 and Health2006/08 serum TSH and FT4 concentrations were analyzed in the cen-
tral laboratory of the University Medicine Greifswald by a homogeneous, sequential, chemilu-
minescent immunoassay based on LOCI1 technology (Dimension Vista1 System Flex1
reagent cartridge; Siemens Healthcare Diagnostics, Inc., Newark, DE). The analytical measur-
ing range was 0.005–100 mIU/mL and 0.1–8.0 ng/dL for TSH and FT4, respectively. In
Inter99, the coefficients of variance (CV) at low, medium and high levels were 2.77%, 2.46%
and 2.28% as well as 3.15%, 2.84% and 3.32% for TSH, respectively. The CVs for FT4 at low,
medium and high levels were 2.33%, 3.31% and 2.96% as well as 3.53%, 2.13% and 3.17% in
Health2006 and Health2008, respectively. The CVs for TSH at low, medium and high levels
Fig 1. Study design. A) Flow diagram of analyses strategies. B) Graphical chart of cross-sectional and longitudinal analyses.
doi:10.1371/journal.pone.0173078.g001
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were 3.71%, 4.10% and 5.15% as well as 2.96%, 3.89% and 4.58% in Health2006 and
Health2008, respectively.
1H-NMR spectroscopic analysis of urinary specimens
After thawing, urine specimens were five minutes centrifuged at 3000g and the supernatant
was used for spectroscopic analysis. Therefore, we mixed 450 μl urine with 50 μl phosphate
buffer to stabilize urinary pH at 7.0 (±0.35). The buffer was prepared with D2O and contained
sodium 3-trimethylsilyl-(2,2,3,3-D4)-1-propionate (TSP) as reference. Spectra were recorded
at the University Medicine Greifswald, Germany, on a Bruker DRX-400 NMR spectrometer
(Bruker BioSpin GmbH, Rheinstetten, Germany) operating at 1H frequency of 400.13 MHz
and equipped with a 4-mm selective inverse flow probe (FISEI, 120 μl active volume) with z-
gradient. Specimens were automatically delivered to the spectrometer via flow injection. The
acquisition temperature was calibrated to 300 ± 0.1K. A standard one-dimensional 1H-NMR
pulse sequence with suppression of the water peak (NOESYGPPR1D) was used: RD—P(90˚)
—4 μsec—P(90˚)—tm—P(90˚)—acquisition of the free induction decay (FID). For each sam-
ple, the non-selective 90˚ hard pulse P(90˚) was individually calibrated in full automation
using the Bruker automation program PULSECAL. The relaxation delay (RD), the mixing
time (tm), and the acquisition time were set to 4 sec, 10 msec, and 3.96 sec, respectively, result-
ing in a total recycle time of ~8.0 sec. Low-power continuous-wave irradiation on the water
resonance at an rf-field strength of 25 Hz was applied during RD and tm for pre-saturation.
1ms Z-Gradients were applied between RD and P(90˚) and between tm and P(90˚) to further
reduce the residual solvent signal. After application of 4 dummy scans, NS 32 were collected
into 65536 (64K) complex data points using a spectral width of 20.689 parts per million (ppm)
and a receiver gain (RG) setting of 128. FIDs were multiplied with an exponential function
corresponding to a line broadening of 0.3 Hz before Fourier-transformation. TopSpin Version
TS2.1pl6 was generally used for automated data acquisition and data processing. Spectra were
automatically phase corrected and automatically referenced to the internal standard (TSP–
0.0 ppm) using Bruker’s processing program APK0.NOE. 18 metabolites were automatically
annotated and quantified using Bruker’s Remote Data Analysis Server. The quantification
approach described in brief: Quantification is done via signal fitting using a simplex algorithm
under consideration of constraints. Constraints are metabolite and signal specific parameters
and their ranges, including: (1) metabolite parameters (molecular mass), (2) parameters/strate-
gies for identification of each considered signal of each metabolite (number of protons, relaxa-
tion time, multiplicity, coupling constant and/or peak patterns, search range for signal
detection), (3) definition of additional signal fit parameters, their start, and allowed minimum
and maximum values (fit range, chemical shift, line width, coupling constant, Gauss-Lorentz-
ratio, baseline offset and slope). Seventeen metabolites were used in the present study. To
account for urine dilution, metabolite concentrations were normalized by urine creatinine lev-
els (metabolites; reported as millimoles per mole of creatinine).
Bucketing of 1H-NMR spectra
Processed spectra were segmented into n = 500 consecutive integrated spectral regions (buck-
ets) of fixed bucket width (0.018 ppm), covering the range from 0.5 ppm to 9.5 ppm (R, R
Foundation for statistical computing, version 3.0.1, Vienna, Austria). The 4.5–5.0 ppm chemi-
cal shift region (28 buckets) was left out of the analysis in order to remove effects of variations
in the suppression of water resonance, and variations in the urea signal caused by partial
cross-solvent saturation through solvent-exchanging protons. To account for urine dilution,
buckets were normalized by urine creatinine levels.
Urinary metabolic profile of thyroid function
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Statistical analysis
Continuous data are expressed as median (1st; 3rd quartile); nominal data as percentage. For
bivariate statistics the Wilcoxon-rank-sum test (continuous data) or χ2-test (nominal data)
were used to compare men and women. For regression analyses, metabolites and buckets were
log2-transformed. TSH concentrations were log-transformed to achieve a more normal-like
distribution. The analysis strategy is displayed in Fig 1. In a first step, linear regression models
were used to assess the cross-sectional associations between metabolites levels or buckets and
FT4 or TSH concentrations in Inter99 and Health2006/08 cohorts. Inter99 was used as discov-
ery cohort and results were dedicated significant if they could be replicated in Health2006/08.
In a second step, two types of longitudinal analyses were performed based on the repeated
measurements in Inter99: I) mixed effect linear models with random intercept were used to
examine the longitudinal association between metabolites or buckets and changes in FT4 or
log(TSH) over time (based on 2396 subjects with 5117 observations). II) Multinomial logistic
regression models were calculated to assess the relation between baseline metabolite levels and
thyroid diseases. Therefore, participants were categorized into three groups according to TSH
levels: 1) sub/overt hypothyroidism (men: TSH> 3.3 mU/l; women: TSH > 4.9 mU/l), 2)
euthyroid (reference group) or 3) sub/overt hyperthyroidism (TSH < 0.4pmol/l). Odds ratios
with 95% confidence intervals (CI) were calculated. All models were adjusted for age, sex,
BMI, HbA1c, LDL cholesterol and systolic blood pressure as well as additionally for coffee con-
sumption in a second model (only Inter99 and cross-sectional analyses). In sensitivity analyses
for the longitudinal mixed linear models we excluded all observation where changes in FT4 or
TSH did not exceed a critical value known as the Reference Change Value (RCV) and thus
were not significant. Variations in a laboratory analyt could be due to biological and analytical
variation. The RCV is given as: RCV ¼ 2
1=2  Z  ðCV2A þ CV
2
I Þ
1=2
with CVA = analytical impres-
sion, CVI = within-subject biological variation and Z = number of standard deviation appro-
priate to the desired probability (in the present study Z = 1.645 for 90% significance). Based on
biological variation for FT4 of 5.7% and for TSH of 19.3% [13] updated every two years:
https://www.westgard.com/biodatabase1.htm] the calculated RCVs were 14.4% and 45.2% for
FT4 and TSH, respectively. The number of used observation reduced from 5117 to 689 for FT4
and 1140 for TSH. To account for multiple testing, we adjusted the p-values by controlling the
false discovery rate (FDR) at 5% using the Benjamini-Hochberg procedure. Statistical analysis
were performed using SAS version 9.4 (SAS statistical software, version 9.4, SAS Institute, Inc;
NC, USA).
Results
General characteristics
General characteristics of the study populations (cross-sectional analyses) are displayed in
Table 1. Participants of Inter99 were on average 5 years younger, more often current smoker,
had a higher BMI and systolic blood pressure as well as a more unfavorable lipid profile than
Health participants. With respect to thyroid hormones, Inter99 subjects had higher FT4 levels
and lower TSH levels compared to the Health2006/08 studies.
Cross-sectional association between metabolites and thyroid function
Adjusted linear regression analyses revealed associations between several urine metabolites
and serum FT4 levels with five metabolites including alanine, glycine, N,N-dimethylglycine,
trigonelline and lactic acid were associated in both study populations (Table 2, Fig 2B). Fur-
thermore, betaine was additionally associated in Health2006/08 and barely missed statistical
Urinary metabolic profile of thyroid function
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significance in Inter 99 (FDR = 0.06). With the exception of trigonelline, all detected metabo-
lites were negatively related to FT4. As trigonelline is known as a biomarker of coffee con-
sumption we additionally adjusted the models in Inter99 for the reported daily coffee intake of
the participants. However, the associations still remained significant [beta 0.102 (standard
error 0.032); FDR<0.05]. With respect to ppm regions, the bucket-based analyses confirmed
the above-mentioned metabolites by showing associations between metabolite-specific ppm
regions and FT4 levels (Fig 2A). Furthermore, inverse relations with FT4 levels were found for
several regions including 1.12–1.16, 1.22–1.25, 6.87–6.90 and 7.35–7.38 ppm in both study
populations (S1 Fig). The doublet observed between 1.12 and 1.16 might be isobutyric acid
[14] a metabolite derived from microbial activity. However, no such assignment was possible
for the remaining spectral parts.
With respect to TSH, four urine metabolites including dimethylamine (DMA), D-glucose-
beta, glycine and lactic acid were significantly (FDR<0.05) and inversely associated in both
study populations (Table 2, Fig 2C). Furthermore, creatinine and betaine, or acetic acid, crea-
tine and 1-methylnicotinamide were related to TSH levels in Inter99 or Health2006/08, respec-
tively. No clear associations to ppm regions based on bucket analyses become apparent in both
populations.
Table 1. General characteristics of the study populations.
Inter99 Health2006/08 P*
(n = 5620) (n = 3788)
Men, % 49.1 44.3 <0.01
Age, years 45 (40; 50) 50 (40; 59)
Smoking, % <0.01
Never smoker 35.3 42.4
Ex-smoker 25.6 32.7
Current smoker 39.2 24.9
BMI, kg/m2 25.6 (23.2; 28.6) 25.1 (22.6; 28.1) <0.01
Diabetes, % 1.8 3.2 <0.01
Systolic BP, mmHg 130 (120; 140) 126 (116; 138) <0.01
Diastolic BP, mmHg 80 (75; 90) 80 (74; 88) <0.01
Total cholesterol, mmol/l 5.4 (4.8; 6.2) 5.0 (4.4; 5.7) <0.01
LDL cholesterol, mmol/l 3.4 (2.8; 4.1) 3.2 (2.6; 3.8) <0.01
HDL cholesterol, mmol/l 1.4 (1.1; 1.7) 1.5 (1.2; 1.8) <0.01
eGFR, 94 (84; 106) 83 (73; 94) <0.01
FT4, pmol/l 15.0 (13.9; 16.3) 12.5 (11.5; 13.6) <0.01
TSH, mU/l 1.25 (0.88; 1.78) 1.49 (1.03; 2.18) <0.01
Coffee consumption, % -
0 cup/day 12.0 -
1 cup/day 6.0 -
2 cup/day 10.7 -
3 cup/day 11.5 -
4 cup/day 13.0 -
5 cup/day 12.7 -
 6 cup/day 34.0 -
Continuous data are expressed as median (1st; 3rd quartile); nominal data as percentage.
*Wilcoxon-rank-sum test (continuous data) or χ2-test (nominal data).
HDL = high-density lipoprotein; LDL = low-density lipoprotein; BP = blood pressure; BMI = body mass index; FT4 = free thyroxine; TSH = thyrotropin.
doi:10.1371/journal.pone.0173078.t001
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Longitudinal association between metabolites and thyroid function
The longitudinal associations between urine metabolites and thyroid function were tested by
mixed linear regression models based on Inter99 data. In general, a decline in mean FT4 and
an increase in log(TSH) levels were observed between the baseline [FT4 15.14 pmol/l); TSH
1.64 mU/l] and 5 year follow-up [FT4 14.84 pmol/l); TSH 1.86 mU/l] possibly indicating a
worsening of the hypothalamic-pituitary-thyroid axis mediated feedback with increasing age.
Urinary level of alanine, DMA, glycine, lactic acid and N,N-dimethylglycine were significantly
(FDR<0.05) associated to changes in FT4 levels (Table 3, Fig 3A). In detail, for all mentioned
metabolites lower levels were related to a higher decline in FT4 levels over time (Fig 3B). With
respect to TSH levels, mixed model analyses revealed significant associations with DMA
(Table 3, Fig 3C).
Longitudinal analyses were further repeated after the exclusion of all observations which
did not achieved the critical RCV of 14.4% for FT4 or 45.2% for TSH (see method section).
The above-described associations between urinary levels of alanine, DMA, lactic acid or N,N-
dimethylglycine and FT4 levels as well as between DMA and TSH were confirmed even if the
FDR-values increased due to the substantially reduced number of observations (Table 3, Fig
3).
Multinomial logistic regression (S1 Table) showed that subjects with higher trigonelline
[per SD increase: OR 1.38 (95%-CI 1.14–1.67), p<0.01, FDR = 0.03] or hippuric acid [per SD
increase: OR 1.27 (95%-CI 1.08–1.50), p<0.04, FDR = 0.07] as well as lower lactic acid [per SD
increase: OR 0.51 (95%-CI 0.31–0.81), p = 0.01, FDR = 0.07], alanine [per SD increase: OR
0.71 (95%-CI 0.51–0.91), p = 0.02, FDR = 0.18] or glycine [per SD increase: OR 0.61 (95%-CI
0.31–1.00), p = 0.04, FDR = 0.24] levels at baseline had an increased risk of hypothyroidism
Table 2. Cross-sectional associations of urinary metabolites with FT4 or TSH concentrations in both study populations.
Metabolite FT4 log(TSH)
Inter99 Health2006/08 Inter99 Health2006/08
Beta (SE) FDR Beta (SE) FDR Beta (SE) FDR Beta (SE) FDR
Acetic Acid -0.016 (0.028) 0.67 -0.074 (0.023) 0.01 -0.018 (0.008) 0.06 -0.024 (0.008) 0.02
Alanine -0.267 (0.046) <0.01 -0.147 (0.041) <0.01 -0.021 (0.014) 0.23 -0.034 (0.015) 0.05
Betaine -0.062 (0.027) 0.06 -0.061 (0.027) 0.04 0.023 (0.008) 0.01 0.018 (0.010) 0.11
Citric Acid -0.007 (0.026) 0.87 -0.055 (0.027) 0.06 0.002 (0.008) 0.87 -0.006 (0.010) 0.62
Creatinine 0.029 (0.043) 0.67 0.095 (0.038) 0.03 -0.054 (0.013) <0.01 -0.014 (0.014) 0.40
Creatine 0.000 (0.021) 0.98 -0.025 (0.016) 0.17 0.001 (0.006) 0.89 -0.026 (0.006) <0.01
Dimethylamine -0.048 (0.077) 0.67 0.034 (0.062) 0.62 -0.079 (0.023) <0.01 -0.068 (0.023) 0.01
Formic Acid 0.068 (0.034) 0.10 -0.051 (0.034) 0.18 -0.009 (0.010) 0.56 -0.011 (0.013) 0.47
D-Glucose-beta 0.072 (0.033) 0.06 0.025 (0.035) 0.54 -0.028 (0.010) 0.01 -0.049 (0.013) <0.01
Glycine -0.062 (0.027) 0.05 -0.090 (0.030) 0.01 -0.023 (0.008) 0.01 -0.030 (0.011) 0.02
Hippuric Acid 0.087 (0.029) 0.01 -0.004 (0.027) 0.87 -0.008 (0.009) 0.56 -0.002 (0.010) 0.85
Lactic Acid -0.183 (0.041) <0.01 -0.140 (0.037) <0.01 -0.035 (0.012) 0.01 -0.064 (0.014) <0.01
N,N-Dimethylglycine -0.098 (0.039) 0.04 -0.083 (0.035) 0.04 -0.007 (0.012) 0.67 -0.030 (0.013) 0.04
Succinic Acid -0.024 (0.043) 0.67 -0.172 (0.036) <0.01 0.005 (0.013) 0.80 -0.021 (0.014) 0.17
Trigonelline 0.112 (0.024) <0.01 0.065 (0.023) 0.02 -0.006 (0.007) 0.57 -0.015 (0.009) 0.11
Trimethylamine -0.047 (0.032) 0.25 -0.071 (0.031) 0.04 0.014 (0.010) 0.23 -0.025 (0.011) 0.05
1-Methylnicotinamide -0.082 (0.045) 0.13 -0.105 (0.044) 0.04 -0.012 (0.014) 0.58 -0.046 (0.017) 0.02
FDR = false discovery rate. SE = standard error; FT4 = free thyroxine; TSH = thyroid-stimulating hormone. Linear regression models were adjusted for age,
sex, body-mass-index, HbA1c, LDL cholesterol and systolic blood pressure.
doi:10.1371/journal.pone.0173078.t002
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(n = 83). No significant association with hyperthyroidism was revealed mainly due to the low
number of cases (n = 41).
Discussion
The present study investigated metabolic alterations in relation to thyroid function. For this
purpose, we analyzed the cross-sectional relation between urinary metabolite concentrations
and FT4 or log(TSH) as well as the longitudinal association to changes in the thyroid function
in two independent populations.
Amino acid metabolism
Cross-sectional analyses revealed negative associations of FT4 levels with the urinary levels of
the glucogenic AAs alanine and glycine as well as lactic acid, betaine and N,N-dimethylglycine
in both study populations. Furthermore, urinary glycine, lactic acid and glucose levels were
inversely related to log(TSH). Previous metabolomics studies already linked urinary excretion
Fig 2. Cross-sectional association between urine metabolome and thyroid function. A) Corrected p-values (false discovery
rate (FDR)) of the cross-sectional associations of metabolites levels (right side) or ppm (left side) with free thyroxine (FT4) or
thyrotropin (TSH) in Inter99 and Health2006/08. Multivariable linear regression models were adjusted for age, sex, body-mass-
index, HbA1c, low-density lipoprotein cholesterol and systolic blood pressure. B) Median levels of alanine, lactate, N,N-
dimethylglycine or trigonelline by tertiles of FT4 in Inter99 and Health2006/08. C): Median levels of glycine, lactate, dimethylamine
or glucose by tertiles of log(TSH) in Inter99 and Health2006/08.
doi:10.1371/journal.pone.0173078.g002
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of glycine, alanine and lactic acid with thyroid function by reporting inverse associations with
FT4 in cross-sectional analyses. In line with the cross-sectional positive association of FT4
(p = 0.03) as well as inverse association of log(TSH) (p<0.01) with urinary glucose in Inter99,
former studies already showed a major role of THs in the regulation of glucose homeostasis by
e.g. increasing gluconeogenesis in the kidney and liver but also glucose absorption and utiliza-
tion in target cells [1, 15]. This was confirmed by higher glucose levels in patients with hyper-
thyroidism and a complex interplay between diabetes and thyroid disease. Furthermore, an
experimental study in rats demonstrated that T4 administration leads besides an increased
rate of glucose production in isolated livers, also leads to an increased transport of alanine in
hepatocytes arguing for an enhanced conversion of alanine into glucose [16]. Studies in
humans confirmed these findings by detecting lower blood levels of alanine and glycine in
hyperthyroidism [17] or after T3 administration [18] in combination with an increased uptake
of these amino acids. The higher uptake of glucogenic AAs might be one reason for the
detected decreasing urinary excretion of alanine and glycine with increasing FT4. A further
reason might be that the FT4 mediated elevated gluconeogenesis rate and thus consequently
increased demand of gluconeogenic precursors resulted in an increased renal resorption of
amino acids like alanine or glycine. THs were shown to have direct renal effects e.g. on glomer-
ular filtration rate and re-absorptive processes. With respect to the latter point, THs influence
the expression and/or activity of various renal channels and transporters [19]. However, not all
studies confirmed decreased serum or urine glucogenic AAs in hyperthyroidism. Among 25
women with thyrotoxicosis the sum of serum glucogenic AAs was elevated, whereas no alter-
ation was found in women with hypothyroidism compared to euthyroid controls [20].
Table 3. Longitudinal associations of urinary metabolites with changes in FT4 or TSH concentrations in Inter99.
Metabolite FT4 Log(TSH)
All subjects subjects with noticeable
change assessed by the
RCV
All subjects subjects with noticeable
change assessed by the
RCV
Beta (SE) FDR Beta (SE) FDR Beta (SE) FDR Beta (SE) FDR
Acetic Acid 0.010 (0.019) 0.70 0.038 (0.103) 0.90 0.000 (0.006) 0.96 -0.017 (0.020) 0.62
Alanine 0.223 (0.034) <0.01 0.792 (0.188) <0.01 -0.001 (0.010) 0.93 -0.009 (0.038) 0.91
Betaine 0.045 (0.020) 0.09 0.291 (0.112) 0.09 -0.004 (0.006) 0.70 -0.005 (0.023) 0.91
Citric Acid -0.032 (0.020) 0.21 -0.101 (0.116) 0.62 0.008 (0.006) 0.29 0.021 (0.022) 0.61
Creatinine -0.020 (0.031) 0.70 -0.044 (0.184) 0.91 0.011 (0.009) 0.42 0.025 (0.035) 0.70
Creatine 0.007 (0.016) 0.73 0.080 (0.087) 0.61 0.004 (0.005) 0.54 0.020 (0.018) 0.48
Dimethylamine 0.201 (0.057) <0.01 0.701 (0.293) 0.10 0.046 (0.017) 0.04 0.159 (0.058) 0.08
Formic Acid -0.047 (0.025) 0.14 -0.215 (0.139) 0.38 -0.006 (0.007) 0.60 -0.034 (0.027) 0.45
D-Glucose-beta -0.013 (0.025) 0.70 -0.014 (0.125) 0.97 0.017 (0.007) 0.09 0.034 (0.026) 0.45
Glycine 0.073 (0.022) 0.01 0.261 (0.122) 0.15 0.015 (0.006) 0.09 0.032 (0.026) 0.45
Hippuric Acid -0.028 (0.021) 0.35 -0.157 (0.122) 0.45 -0.013 (0.006) 0.11 -0.051 (0.025) 0.15
Lactic Acid 0.121 (0.031) <0.01 0.540 (0.164) 0.02 0.013 (0.009) 0.29 0.002 (0.032) 0.97
N,N-Dimethylglycine 0.128 (0.030) <0.01 0.408 (0.162) 0.09 0.003 (0.009) 0.79 -0.020 (0.035) 0.76
Succinic Acid -0.034 (0.032) 0.48 -0.070 (0.172) 0.90 0.004 (0.010) 0.73 0.023 (0.036) 0.74
Trigonelline -0.037 (0.019) 0.13 -0.192 (0.106) 0.25 -0.010 (0.006) 0.16 -0.025 (0.020) 0.45
Trimethylamine 0.055 (0.025) 0.09 0.193 (0.139) 0.45 0.004 (0.007) 0.70 -0.009 (0.029) 0.91
1-Methylnicotinamide -0.020 (0.037) 0.70 0.002 (0.200) 0.99 0.022 (0.011) 0.14 0.087 (0.041) 0.15
FDR = false discovery rate. SE = standard error; FT4 = free thyroxine; TSH = thyroid-stimulating hormone; RCV = reference change value (RCV; p = 0.1).
Mixed linear models were adjusted for age, sex, body-mass-index, HbA1c, LDL cholesterol and systolic blood pressure.
doi:10.1371/journal.pone.0173078.t003
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Moreover, a population-based cohort even found no association between FT4 levels and
serum levels of glucogenic AAs including glycine, valine, serine or proline in euthyroid sub-
jects [9]. Interestingly in contrast to the cross-sectional findings in the present study, longitudi-
nal analyses revealed that subjects with high baseline urinary levels of alanine, glycine and
lactate exhibit a smaller decrease or even an increase in FT4 over time in Inter99. One explana-
tion for these discrepancies might be the initial lower FT4 levels in subjects with high metabo-
lite levels at baseline (cross-sectional analyses). However, the adjustment for baseline FT4
levels did not changed the results substantially (data not shown). Given the general worsening
of the hypothalamic-pituitary-thyroid axis mediated feedback over time this observation may
imply a change in this system based on the metabolic state of the individual, e.g. high urine lev-
els of alanine predict an increase in FT4 whereas low levels predict a decrease over time. The
change in FT4 could be seen as a response to the metabolic state of the individual rather than
reflecting the actual effect of FT4 on metabolism. Following this suggestions, urine metabo-
lome analyses provide potential to predict the individual thyroid state. Unfortunately, the low
number of thyroid disease in the present study population limits the evaluation of the clinical
utility of these findings.
Besides increased uptake of glycine for gluconeogenesis even a decreased production could
account for this finding. In this respect the aligned change in betaine and N,N-dimethylglycine
in cross-sectional and longitudinal analyses are of particular interest. Betaine-homocysteine S-
methyltransferase facilitates the conversion of homocysteine to methionine requiring betaine
as methyl donor and producing dimethylglycine, which could be further converted to
Fig 3. Longitudinal association between urine metabolome and thyroid function. A) Corrected p-values (false discovery rate
(FDR)) of the longitudinal associations of urine metabolites levels (right side) or ppm (left side) with changes in free thyroxine (FT4)
or thyrotropin (TSH) in Inter99. Models were performed in all subjects (x-axis) and *only in subjects with noticeable change
assessed by the reference change value (RCV). Multivariable mixed linear models were adjusted for age, sex, body-mass-index,
HbA1c, low-density lipoprotein cholesterol and systolic blood pressure (for more details see method section). Estimated mean value
with 95% confidence limits for changes in free thyroxine (B: ΔFT4) or thyrotropin (C: Δlog(TSH)) by quartiles of selected urinary
metabolite concentrations in Inter99 calculated by mixed linear models. DMA = dimethylamine. DMG = dimethylglycine.
doi:10.1371/journal.pone.0173078.g003
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sarcosine and finally to glycine via sarcosine dehydrogenase activity. Interestingly, a suppres-
sive effect of TH in animal models on (hepatic) betaine-homocysteine S-methyltransferase
activity was reported [21, 22]. However, the suspected increased availability of betaine might
be blunted through a general down regulation of this pathway.
Coffee metabolism
Beside metabolites linked to amino acid metabolism, a strong positive association between uri-
nary trigonelline levels and FT4 was detected. An association with the urine excretion of trigo-
nelline was previously reported with respect to the TH metabolite 3,5-T2 in a large sample of
euthyroid subjects [11]. The formation of 3,5-T2 in vivo is still under debate but early studies
suggested its endogenous origin from either T3 or T4, mainly as an inactivating step in the
local control of T3 action [23]. It has to be noted, that up to now no clear relation between
3,5-T2 and the classical TH is established in humans [24]. Given the disappearance of this
strong association in the longitudinal analyses an altering effect of trigonelline in the conver-
sion or clearance of TH is likely. Trigonelline is known as an metabolite in the niacin metabo-
lism and is found in many plants including fenugreek seeds, oat or potatoes and further
represents a bioactive compound in coffee with a concentration ~1% [25]. Studies suggest that
trigonelline is not substantially metabolized in the human body and is mostly excreted in urine
[25, 26]. Therefore trigonelline is listed as an urinary marker of coffee consumption [27].
Regarding thyroid function it is suggested that coffee consumption altered the intestinal
absorption of L-T4, the synthetic thyroid hormone equivalent used to treat hypothyroidism.
Among several patients a lower incremental rise of serum T4 and a missing or incomplete nor-
malization of TSH following oral L-T4 administration together with coffee were observed [28–
30]. Unfortunately no further research regarding trigonelline and thyroid health is available up
to now. Therefore, we could only speculate about the reason of the association between trigo-
nelline and FT4. Coffee represents a complex mixture of more than 1000 partly bioactive com-
pounds including beside caffeine and its metabolites paraxanthine, theobromine and
theophylline, a high number of further molecules like trigonelline, phenolic acids, kahweol or
cafestol [25]. Furthermore, urinary hippuric acid levels, as possible metabolite of coffee com-
ponents, were revealed to be associated with coffee consumption [31] and showed the same
association with FT4 levels as trigonelline in the Inter99 cohort. During the last decade several
investigations dealt with the pleiotropic effects of coffee and/or its components on the metabo-
lism and health status [32, 33]. Experimental studies suggested overlapping actions of caffeine/
coffee [32–34] with THs [1, 15, 35] including increased metabolic rate, increased blood pres-
sure or reduced insulin sensitivity. However, in general these caffeine/coffee specific effects are
subject of a controversial debate and were not always confirmed. Regarding THs, an over 30
year old study investigated the effect of theophylline administration every 12 hour for 60 hour
on the pituritary-thyroid axis in four healthy adults [36]. Plasma total T4 levels showed a
simultaneous increase with theophylline levels over the whole experiment time and were
accompanied by an increase in plasma as well as urinary cyclic adenosine 3’,5’-monophosphate
(cAMP) levels. The authors suggested that a theophylline mediated increase in intracellular
cAMP led to the observed increase in T4 production. It has to be noted, that within the same
study children treated with theophylline because of asthma showed a transient increase in
plasma T4, which would fit to the disappearance of the FT4—trigonelline association in longi-
tudinal analyses. Moreover, an expected hyperthyroid state leading to a hypermetabolic state
was attenuated by an increased peripheral conversion of T4 to reverse T3, a less metabolic
active TH metabolite. Implying even 3,5-T2 as metabolic degradation product of T4 this might
link the previously mentioned association between 3,5-T2 and urinary trigonelline. However,
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theophylline is assumed to inhibit cyclic nucleotide phosphodiesterase and prevent the break-
down of cAMP which consequently lead to increased cAMP levels [37]. cAMP plays a major
role in thyroid action. The binding of TSH to the G protein-coupled TSH receptor stimulates
among others the cAMP production resulting in TH production and secretion via various
intra-cellular mechanisms. Theophylline represents only one metabolite of caffeine in the
group of methylxanthine and it remains unclear if other metabolites exhibit similar actions.
Dimethylamine (DMA)
In the present study, urinary DMA was inversely associated with log(TSH) in cross-sectional
analyses. Furthermore, low urinary DMA levels were related to a higher increase in log(TSH)
and a higher decrease in FT4 over time. DMA is one of the most abundant components of the
human urine and exogenous as well as endogenous sources of DMA are known [38]. Food
components including trimethylamine, trimethylamine N-oxide, lecithin and choline have
been found to increase urinary excretion of DMA and in particular after the consumption of
fish and seafood an urinary DMA rise was observed [38, 39]. These metabolites are degraded
by microbes yielding DMA. Interestingly, even the putative isobutyric acid (doublet between
1.12 and 1.16 ppm) is a proxy of microbial activity as fermentation product of dietary fibers.
An influence of the thyroid hormone state on the microbiome might be mediated by altered
bile acid production [40] which are well known to affect the composition of the gut micro-
biome [41]. Moreover, endogenous asymmetric dimethylarginine (ADMA), known as inhibi-
tor of nitric oxide (NO) synthesis, can be directly degrade by dimethylaminohydrolase
(DDAH) to the renally cleared products DMA and citrulline [42–44]. It is suggested that
ADMA represents one major source for urinary DMA [45]. A recently published population-
based study revealed that ADMA was cross-sectional related to low TSH levels as well as posi-
tively related with FT4 [46]. These results were confirmed in patients with Graves’ disease [47]
or hyperthyroidism [48, 49] and therefore fit in with our longitudinal findings of a higher
decrease in FT4 levels among subjects with low DMA. Furthermore, experimental studies con-
firmed a relationship between ADMA and thyroid function by showing a down-regulation of
the DDAH1 gene in mice liver following T3 treatment [50] as well as the production of endoge-
nous ADMA in primary human thyrocytes [51]. Beside ADMA the consumption of fish and
seafood represent one source of DMA and therefore DMA might be marker of the dietary
intake of iodine. A large Danish study could show that fish account for around 15% of iodine
intake in adults [52] and it is well accepted that iodine is an essential element to thyroid func-
tion and in particular the production of thyroid hormone [53]. Thus one can speculate that a
higher DMA levels are related to higher fish consumption and consequently to higher iodine
intake and a better thyroid function. However these assumptions are speculative and further
research is needed to identify behind the association of high DMA with a lower decrease of
FT4 over time.
Conclusion
The present study demonstrated associations of thyroid function with amino acids including
glycine, betaine or N,N-dimethylglycine as well as glucose or lactic acid, and therefore sup-
ports previous studies arguing for an important role of THs in the regulation of glucose
homeostasis. In addition, the predictive character of these metabolites might argue for a poten-
tial feedback of the metabolic state on thyroid function. Furthermore, the urine excretion of
trigonelline, a marker of coffee consumption, was linked to the thyroid function. However, the
coffee specific effects on thyroid health are unknown up to now and need to be further investi-
gated keeping in mind the ubiquitous consumption of the beverage.
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